Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

Introduction Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of a...

Full description

Saved in:
Bibliographic Details
Main Authors: Lisa M Butler, Anthony M Joshua, Tahlia Scheinberg, James Kench, Martin Stockler, Kate L Mahon, Lucille Sebastian, Phillip Stricker, H Woo, Ruban Thanigasalam, Nariman Ahmadi, Margaret M Centenera, Lisa G Horvath
Format: Article
Language:English
Published: BMJ Publishing Group 2020-01-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/1/e033667.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items